Accustem Sciences

AccuStem Sciences, Inc. is a clinical stage diagnostics company, which engages in medical practice activities. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2022-03-01. The company is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. The company focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.